|
This company has over $71.4 million is cash and two large partners (Johnson & Johnson and Hoechst Marion Roussel) paying for all the development costs for its 2 lead products and the partners have taken equity stakes in the company. The first product is Oxygent (perflubron emulsion), a temporary blood subsitute that works with all blood types, has a shelf life of over 18 months and has a low production cost. Liquivent is their other main product for acute respiratory failure. Everyone knows that market potential for a blood substitute, and I think ALLP will be the winner with the most simple, cost effective solution. Both products are in stage II trials. Any comments? |
